The relationship between polyphenols and miRNAs: A novel therapeutic strategy for metabolic associated fatty liver disease

被引:12
|
作者
Bayram, Hatice Merve [1 ]
Eren, Fatih [2 ,3 ]
Gunes, Fatma Esra [4 ]
机构
[1] Istanbul Gelisim Univ, Dept Nutr & Dietet, Fac Hlth Sci, Istanbul, Turkey
[2] Marmara Univ, Inst Gastroenterol, Istanbul, Turkey
[3] Marmara Univ, Dept Med Biol, Sch Med, Istanbul, Turkey
[4] Marmara Univ, Dept Nutr & Dietet, Fac Hlth Sci, Istanbul, Turkey
来源
HEPATOLOGY FORUM | 2021年 / 2卷 / 03期
关键词
Metabolic-associated fatty liver disease; microRNA; polyphenols; NONALCOHOLIC STEATOHEPATITIS; CHOLESTEROL-METABOLISM; CIRCULATING MICRORNAS; LIPID-ACCUMULATION; INSULIN-RESISTANCE; DOWN-REGULATION; IN-VIVO; EXPRESSION; MIR-122; ACID;
D O I
10.14744/hf.2021.2021.0037
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Metabolic-associated fatty liver disease (MAFLD) is a public health problem that is increasingly recognized, currently affecting up to a quarter of the world's adult population. Although a biopsy is the current gold standard to diagnose MAFLD, there are potentially serious complications, making it inadequate. Thus far, noninvasive methods have not been able to determine the stage and the subtype of MAFLD. The development and prognosis of MAFLD are modulated by epigenetic factors, including microRNAs (miRNAs), which may be potential biomarkers for MAFLD. Polyphenols, found in many fruits and vegetables, may be useful, as they alter gene expression with epigenetic factors, such as miRNAs. This review presents an overview of the relationship between polyphenols and miRNAs in MAFLD. The literature suggests that miRNAs could be used as a diagnostic method for MAFLD, especially miRNA-122 and miRNA-34a. However, though it has been demonstrated that polyphenols may contribute to improving MAFLD, to our knowledge, no study to date has shown the relationship between polyphenols and miRNAs in MAFLD. The exact mechanisms of polyphenols on miRNAs in MAFLD remain unclear. Future studies may provide hope for diet therapy for MAFLD patients as well as the development of polyphenol-related foods or drugs that target miRNAs to treat MAFLD.
引用
收藏
页码:128 / 136
页数:9
相关论文
共 50 条
  • [31] Metabolic associated fatty liver disease (MAFLD): a milestone in the history of fatty liver disease
    Alharthi, Jawaher
    Eslam, Mohammed
    HEPATOBILIARY SURGERY AND NUTRITION, 2021, 10 (05) : 696 - 698
  • [32] RELATIONSHIP BETWEEN PRESENCE OF METABOLIC DYSFUNCTION ASSOCIATED FATTY LIVER DISEASE AND CHANGE IN LIVER STIFFNESS IN INDIVIDUALS WITH CHRONIC HEPATITIS B
    Patmore, Lesley Ann
    Van Eekhout, Kirsi
    Koc, Ozgur Mustafa
    De Knegt, Rob J.
    Janssen, Harry L. A.
    Kramer, Matthijs
    Brouwer, Willem Pieter
    Honkoop, Pieter
    De Bruijne, Joep
    Boland, Greet
    De Man, Robert A.
    Takkenberg, Bart
    Sonneveld, Milan J.
    HEPATOLOGY, 2023, 78 : S490 - S491
  • [33] Transcription factors, metabolic dysfunction-associated fatty liver disease, and therapeutic implications
    Hu, Shuwei
    Ai, Yingjie
    Hu, Chencheng
    Bawa, Fathima N. Cassim
    Xu, Yanyong
    GENES & DISEASES, 2025, 12 (03)
  • [34] Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH
    Goedeke, Leigh
    Shulman, Gerald, I
    MOLECULAR METABOLISM, 2021, 46
  • [35] Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease
    Suzuki, Keito
    Tamaki, Nobuharu
    Kurosaki, Masayuki
    Takahashi, Yuka
    Yamazaki, Yudai
    Uchihara, Naoki
    Tanaka, Yuki
    Miyamoto, Haruka
    Yamada, Michiko
    Keitoku, Taisei
    Okada, Risa
    Higuchi, Mayu
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Nakanishi, Hiroyuki
    Izumi, Namiki
    HEPATOLOGY RESEARCH, 2024, 54 (06) : 600 - 605
  • [36] Targeting Galanin Receptor Signaling as a Novel Therapeutic Strategy for the Treatment of Fatty Liver Disease
    DeMorrow, Sharon
    Williams, Elaina
    An, Su Yeon
    Venter, Julie
    Choi, Won Seog
    Nadeem, Yusra
    Chu, Christopher
    Petrescu, Anca
    FASEB JOURNAL, 2022, 36
  • [37] Overlapping group between non-alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research
    Cheng, Yu-Ming
    Hsieh, Tsung-Han
    Wang, Chia-Chi
    Kao, Jia-Horng
    JGH OPEN, 2024, 8 (10):
  • [38] Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome
    Sinn, Dong Hyun
    Kang, Danbee
    Choi, Sung Chul
    Hong, Yun Soo
    Zhao, Di
    Guallar, Eliseo
    Park, Yewan
    Cho, Juhee
    Gwak, Geum-Youn
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (07) : 1873 - +
  • [39] Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
    Younossi, Zobair M.
    Paik, James M.
    Al Shabeeb, Reem
    Golabi, Pegah
    Younossi, Issah
    Henry, Linda
    HEPATOLOGY, 2022, 76 (05) : 1423 - 1437
  • [40] Association between Impaired Ketogenesis and Metabolic-Associated Fatty Liver Disease
    Bae, Jaehyun
    Lee, Byung-Wan
    BIOMOLECULES, 2023, 13 (10)